Search and filter stories that passed editorial review. Evidence strength, regulatory status, and guideline position are shown separately and are never inferred from one another.
51 verified discoveries match your filters.
An investigational NSCLC vaccine (BNT116) is being tested in an ongoing, open-label, first-in-human trial (estimated enrollment 320, sponsor BioNTech SE) with multiple treatment cohorts, primarily to establish safety (dose-limiting toxicities,…
Primary source cited
Last reviewed
In this prospective cohort, plasma KRAS ctDNA positivity correlated with worse survival and higher metastatic progression, while peritoneal KRAS ctDNA positivity correlated with occult/peritoneal metastatic risk — two related but…
Primary source cited
Last reviewed
Across two validation cohorts, an 18-gene urine test (MPS2) substantially outperformed PSA alone (AUC 0.81–0.82 vs. 0.60) for detecting higher-grade prostate cancer, with modeled reductions in unnecessary biopsies, including in…
Primary source cited
Last reviewed
In mismatch repair-deficient rectal cancer specifically, dostarlimab produced a high rate of clinical complete response — most of it sustained at 12 months, with 92% two-year recurrence-free survival across the…
Primary source cited
Last reviewed
The study shows that the personalized vaccine can generate long-lived cancer-specific T-cell responses and that those responses were associated with longer recurrence-free survival in this small Phase I cohort. A…
Primary source cited
Last reviewed
A specific expanded FDA approval exists for trastuzumab deruxtecan in a defined HR-positive, HER2-low/ultralow metastatic breast cancer population after endocrine therapy, based on a significant progression-free-survival benefit in DESTINY-Breast06.
Primary source cited
Last reviewed
In the randomized, placebo-controlled ADRIATIC trial, durvalumab given as consolidation therapy after concurrent chemoradiotherapy meaningfully extended both overall survival and progression-free survival compared with placebo in limited-stage small cell lung…
Primary source cited
Last reviewed
PT217 (peluntamig), an investigational bispecific antibody targeting DLL3 and CD47, is being tested in an ongoing, open-label, first-in-human, Phase 1/2 trial (SKYBRIDGE), primarily to establish safety and an appropriate dose…
Primary source cited
Last reviewed
In the randomized, double-blind, placebo-controlled INAVO120 trial, adding inavolisib to palbociclib and fulvestrant significantly delayed disease progression compared with palbociclib and fulvestrant alone, in a PIK3CA-mutated, endocrine-resistant, first-line metastatic breast…
Primary source cited
Last reviewed
In the randomized, double-blind, placebo-controlled INDIGO trial, vorasidenib significantly delayed disease progression (by blinded independent review) and delayed the time to the next anticancer intervention, compared with placebo, in a…
Primary source cited
Last reviewed